Please login to the form below

Not currently logged in
Email:
Password:

Ablynx reshuffles its board again

Dr Bo Jesper Hansen resigns from the Belgium biotech's board

Dr Bo Jesper HansenAfter one month as Ablynx’s chairman of the board of directors, Dr Bo Jesper Hansen (pictured) has resigned from the position due to personal reasons.

Dr Hansen will be succeeded by Dr Russell Greig, who will also become a permanent representative of Greig Biotechnology Global Consulting.

Dr Greig has been non-executive director of Ablynx since 2012, and has been unanimously elected by the board to be the biotech’s new chairman.

To date he has served in various roles during his 28-year career at GlaxoSmithKline, where he most recently served as president for both GSK Pharmaceuticals and SROne, the venture arm of GSK.

Dr Edwin Moses, chief executive officer of Ablynx, said: “We are very fortunate to have a very suitable successor for Bo Jesper, allowing for an orderly transition at this time.

“Russell knows the company extremely well and will be an important asset during the next months.”

14th February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics